These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15099545)

  • 1. Warfarin for atrial fibrillation: the end of an era?
    Donnan GA; Dewey HM; Chambers BR
    Lancet Neurol; 2004 May; 3(5):305-8. PubMed ID: 15099545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
    Connolly SJ
    Am Heart J; 2003 Mar; 145(3):418-23. PubMed ID: 12660663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet; 1996 Sep; 348(9028):633-8. PubMed ID: 8782752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
    Stewart RA
    Curr Opin Cardiol; 2011 Jul; 26(4):294-9. PubMed ID: 21537165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
    Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
    Reiffel JA
    Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and management of atrial fibrillation.
    Ali S; Hong M; Antezano ES; Mangat I
    Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):233-44. PubMed ID: 17378769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.